No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Perioperative Durvalumab with Neoadju-vant Chemotherapy Improved Survival in Operable Bladder Cancer

byJinny TsangandAlisha Yi

September 27, 2024

in StudyGraphics

Reading Time: 1 min read

Click here to read this study in NEJM.

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Immunosuppression with systemic glucocorticoids close to initiation of immune checkpoint inhibitor is associated with worse survival outcomes

Neoadjuvant chemotherapy does not improve disease-free survival in patients with locally advanced colon cancer

Camrelizumab may be safe and effective in the management of locally advanced esophageal squamous cell carcinoma

#VisualAbstract Telehealth vs In-Person Early Palliative Care for Patients with Advanced Lung Cancer

RelatedReports

Chronic Disease

Immunosuppression with systemic glucocorticoids close to initiation of immune checkpoint inhibitor is associated with worse survival outcomes

May 25, 2026

Development of a risk index for colorectal cancer screening

Chronic Disease

Neoadjuvant chemotherapy does not improve disease-free survival in patients with locally advanced colon cancer

March 25, 2026

Hybrid minimally invasive esophagectomy associated with lower complication rates compared to open esophagectomy

Chronic Disease

Camrelizumab may be safe and effective in the management of locally advanced esophageal squamous cell carcinoma

March 19, 2026

StudyGraphics

#VisualAbstract: Vepdegestrant Increased Progres-sion-Free Survival in Advaced Breast 2m TM Cancer with ESR1 Mutations

August 22, 2025

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

2 Minute Medicine Rewind September 30, 2024

#VisualAbstract: Pembrolizumab Increases Survival in Early-Stage Triple-Negative Breast Cancer

One-year of Herceptin preferable to two-year regimen

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result